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Abstract
Purpose Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) reveals altered cerebral metabolism
in individuals with mild cognitive impairment (MCI) and Alzheimer’s dementia (AD). Previous metabolic connectome
analyses derive from groups of patients but do not support the prediction of an individual’s risk of conversion from
present MCI to AD. We now present an individual metabolic connectome method, namely the Kullback-Leibler
Divergence Similarity Estimation (KLSE), to characterize brain-wide metabolic networks that predict an individual’s
risk of conversion from MCI to AD.
Methods FDG-PET data consisting of 50 healthy controls, 332 patients with stable MCI, 178 MCI patients progressing to AD,
and 50 AD patients were recruited from ADNI database. Each individual’s metabolic brain network was ascertained using the
KLSE method. We compared intra- and intergroup similarity and difference between the KLSE matrix and group-level matrix,
and then evaluated the network stability and inter-individual variation of KLSE. The multivariate Cox proportional hazards
model and Harrell’s concordance index (C-index) were employed to assess the prediction performance of KLSE and other
clinical characteristics.
Results The KLSE method captures more pathological connectivity in the parietal and temporal lobes relative to the
typical group-level method, and yields detailed individual information, while possessing greater stability of network
organization (within-group similarity coefficient, 0.789 for sMCI and 0.731 for pMCI). Metabolic connectome expres-
sion was a superior predictor of conversion than were other clinical assessments (hazard ratio (HR) = 3.55; 95% CI,
2.77–4.55; P < 0.001). The predictive performance improved further upon combining clinical variables in the Cox
model, i.e., C-indices 0.728 (clinical), 0.730 (group-level pattern model), 0.750 (imaging connectome), and 0.794 (the
combined model).
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Conclusion The KLSE indicator identifies abnormal brain networks predicting an individual’s risk of conversion from MCI to
AD, thus potentially constituting a clinically applicable imaging biomarker.
Keywords Alzheimer’s disease .Mild cognitive impairment . Connectome . FDGPET . Conversion prediction
Introduction
With currently some 50million cases worldwide, Alzheimer’s
disease (AD) is the most common cause of dementia, and its
prevalence is projected to grow rapidly over the next decades
[1]. Mild cognitive impairment (MCI) is a preclinical stage of
AD, in which individuals are free from overt cognitive and
behavioral symptoms, but are showing subtle prodromal signs
of dementia [2]. A subgroup ofMCI individuals has especially
high risks for imminent progression to AD, while the remain-
der may undergo no further cognitive decline in the coming
years. Given the unpredictable course of MCI, it is important
to develop sensitive biomarkers and predictors of an individ-
ual’s risk of progression from MCI to AD.
Various recent studies show that biomarkers derived from
18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) can accurately predict conversion from MCI to
AD [3–5]. In particular, machine learning and deep learning
tools have successfully classified different prodromal stages in
this conversion. An FDG-PET study using multi-scale deep
convolutional neural network analysis to predict future cogni-
tive decline in MCI patients, attained a predictive accuracy of
84.2% [6]. Applying an optimized semi-quantitative FDG-
PET method, Pagani et al. correctly identified 89% of MCI
patients who converted to ADwithin 5 years of follow-up [7].
Notably, Blazhenets et al. proposed a novel method with spa-
tial covariance mapping of the FDG-PET signal to identify an
AD conversion-related pattern of cerebral metabolism [8].
These methods emphasize regional FDG uptake or quantita-
tive characteristics of metabolically abnormal regions in PET
images, without fully considering the metabolic interactions
of between-regions, thus potentially losing relevant informa-
tion related to concerning individual differences in metabolic
topology.
In contrast to earlier work on group-based metabolic pat-
terns, brain network analysis based on graph theory could
offer an individualized assessment of metabolic patterns pre-
dictive of conversion. Brain network science has already con-
tributed to obtain a better understanding of the pathophysiol-
ogy of AD [9]. Furthermore, it has delineated local and global
brain metabolic abnormalities typical for MCI and AD, while
affording an effective diagnostic biomarker to identify AD at
an early phase [10, 11]. Recently, a series of novel analytic
methodologies have been proposed to investigate metabolic
networks in PET imaging [12, 13]. The metabolic connections
in FDG-PET images are typically estimated via regional
differences in standard uptake value (SUV), which is a surro-
gate index of the cerebral metabolic rate for glucose.
However, most of the metabolic connectome studies have
hitherto adopted group-level network methods for metabolic
network modeling. For example, some FDG-PET studies de-
rive functional metabolic connectivity networks using sparse
inverse covariance estimation [13], while other studies imple-
mented the Pearson’s correlation to obtain group-level meta-
bolic networks [12, 14]. While successful in revealing net-
work abnormalities in clinical groups, we point out that such
group-level metabolic network analyses sacrifice critical
individual-level information.
Inspired by MR-based structural studies using the
Kullback-Leibler divergence similarity estimation (KLSE)
[15–17], we now apply the concept of relative entropy to
develop a new analytic methodology for individual-level met-
abolic brain network construction in FDG-PET imaging. By
FDG-PET images from the Alzheimer ’s Disease
Neuroimaging Initiative (ADNI) database, we test the KLSE
method for predicting the conversion of MCI to AD as
assessed with clinical follow-up. We firstly establish the va-
lidity and efficacy of the relative entropy concept to construct
a metabolic network for each subject and secondly use the
KLSE indicators to predict the risk of conversion in MCI
patients during a 3-year follow-up.
Methods
Kullback-Leibler divergence similarity estimation
method
The KLSE method has been successfully implemented
with structural MRI data for individual morphological
brain network analysis [15–17], but has not yet been used
for constructing individual metabolic networks from FDG-
PET imaging. We suppose that the FDG-PET signal across
brain regions indicates metabolic connections subserving
inter-regional information transfer. The relatively high
resting signal-to-noise FDG-PET signal in a volume of in-
terest (VOI) reflects the relative glucose metabolism rate,
i.e., energy consumption demand of this region. Regional
metabolism indexed by local FDG radiotracer uptake is an
index of afferent synaptic activity [18–20]. This putative
relationship offers a plausible approach to characterize
inter-neuronal information transfer. Statistical relationships
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of the similarity of cerebral glucose metabolism in any two
regions depicted through KLSE (the relative entropy) can
then delineate individual metabolic connections, as sum-
marized in Fig. A1.
For globally normalized FDG uptake maps, the intensity of
voxels within each of n specific VOIs are extracted and used
to estimate the probability density function (PDF) of this VOI
using non-parametric kernel density estimation.
We next derived the metabolic connections as the symmet-
ric Kullback-Leibler (KL) divergence (relative entropy), ac-
cording to the mathematical equation:
DKL P‖Q
 
¼ ∫
X
P xð Þlog P xð Þ
Q xð Þ þ Q xð Þlog
Q xð Þ
P xð Þ
 
dx ð1Þ
where P and Q represent the probability density functions
(PDFs) of voxel intensities in a pair of VOIs. Finally, we
calculated the metabolic connectivity strength of pairwise
VOIs by KL divergence as follows:
KLS

Pj Qj Þ ¼ e−DKL P‖Q
 
ð2Þ
As a measure of metabolic connectivity, we obtained an
adjacency matrix from the KLSE. This adjacency matrix de-
scribes pairwise metabolic connectivity, where each ijth ele-
ment of this matrix denotes the metabolic connection strength
between region i and j.
Materials
To validate the effectiveness of KLSE in individual metabolic
connectome networks and to test its applicability in predicting
the risk of MCI conversion, we conducted a series of experi-
ments, as summarized in Fig. 1. After constructing individual
metabolic networks via our KLSE method, we compared
intra- and intergroup similarity and difference between the
KLSE and group-level matrices by using Pearson’s correla-
tion. Then, we applied KLSE individual metabolic network
analysis to characterize MCI-conversion indicators, thus de-
fining an image-derived biomarker to predict the individual
risk of conversion from MCI to AD.
Subjects
The data used in this study were obtained from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) data-
base (adni.loni.usc.edu) and its extensions. The primary goal
of ADNI has been to test whether serial MRI, PET, other
biological markers, and clinical and neuropsychological
assessment can be combined to predict and measure the
progression of MCI and early AD. The institutional review
boards of ADNI provided review and approval of the ADNI
data collection protocol. Written, informed consent had been
obtained from each subject.
We investigated two independent cohorts of subjects with
baseline FDG-PET images collected from the ADNI
sMCI group
pMCI group
AAL 
parcellation
FDG-PET image 
preprocessing
sMCI networks pMCI networks
Individual metabolic network
(KLSE methodology)
Group metabolic network
(Pearson corr) 
sMCI network pMCI network
Inter-individual dissimilarity 
assessment
Intra-group stability assessment
Intra- and intergroup 
similarity assessment
Average KLSE metabolic 
network 
Group-level metabolic 
network
KLSE validation
Metabolic network construction
LASSO feature 
selection
s1
sp
s2
...
Network properties extraction
KLSE indicators 
linear combination 
Clinical 
information
KLSE application in MCI conversion
Fig. 1 The flowchart of experimental procedures in this study
2755Eur J Nucl Med Mol Imaging (2020) 47:2753–2764
databases. Our cohort A contained 510 subjects with either
stable MCI (sMCI, n = 332) or progressive MCI (pMCI, n =
178) with clinical follow-up; we used the FDG-PET images
from this cohort to established predictive modeling and to test
the validity of our models. Our cohort B consisted of 50 AD
patients and 50 age/gender-matched healthy controls; we used
the FDG-PET images from this cohort to evaluate the diag-
nostic utility of our predictive models.
Detailed eligibility criteria for these participants are shown
in Fig. A2. In brief, eligible participants with MCI underwent
FDG-PET scanning and clinical cognitive evaluations at base-
line and were clinically followed-up during at least 36 months.
These MCI participants were stratified post hoc as (1) stable
MCI subjects with baselineMCI diagnosis (including early and
late MCI) who had not converted to AD at follow-up, and (2)
progressive MCI patients who had converted to AD within the
follow-up interval. All cases with ultimate AD diagnosis satis-
fied the diagnostic criteria according to the National Institute of
Neurological and Communicative Disorders and Stroke and
Alzheimer’s disease and Related Disorders Association [21].
Equal numbers of cohort A subjects were randomly assigned to
training or test datasets using a computer-generated randomi-
zation list. The demographic and clinical characteristics of all
participants are summarized in Table 1. The clinical character-
istics did not significantly differ between training and test
datasets for the sMCI or pMCI subgroups (P > 0.05). There
were significant differences in age, MMSE score, and APOE
ε4 positivity between the sMCI and pMCI groups, but no be-
tween training and test datasets.
FDG-PET images acquisition and preprocessing
Baseline FDG-PET images in a state of rest were acquired 30–
35 min after administration of 185 ± 18.5 MBq FDG, with
acquisition details as outlined in the study protocols of the
ADNI database. The images were spatially normalized to a
PET template in Montreal Neurological Institute (MNI) brain
space and smoothened with a Gaussian filter of 8 mm full-
width at half-maximum (FWHM). Individual PET images
were intensity normalized to the global mean brain uptake
and automatically parcellated into 90 regions of interest
(ROIs) defined by the automated anatomical labeling (AAL)
atlas. All preprocessing was performed using Statistical
Parametric Mapping software (SPM12; Wellcome
Department of Imaging Neuroscience, Institute of
Neurology, London, UK) implemented in MATLAB 2016b
(MathWorks Inc., Sherborn, MA).
KLSE metabolic network construction
For depicting the individual metabolic network, we represent
brain nodes by 90 telencephalic VOIs from the AAL atlas
parcellation. Globally normalized FDG uptake in each VOI
was used to generate a region × region correlation matrix
(90 × 90) for each subject. We applied the KLSE method to
individual FDG-PET image to construct a correlation matrix
which included pairwise regional metabolic connections. PET
images of all participants underwent individual metabolic net-
work construction for further analysis. Figure A3 shows an
individual metabolic network topography of one representa-
tive sMCI subject (male; age, 72 years; MMSE, 30; APOE4,
negative) and one pMCI subject (male; age, 70 years; MMSE,
27; APOE4, positive). Using the KLSE method, significant
individual differences in these two brain network
connectomes are conspicuous.
KLSE validation
In this step, we implemented three evaluation experiments to
characterize the validity and effectiveness of KLSE.
Table 1 Clinical and baseline demographic characteristics of all participants
Cohort Group Sex (M/F) Age (years) Education (years) MMSE score APOE ε4 positive rate
Cohort A Training dataset
(n = 255)
sMCI (n = 166) 90/76 71.2 ± 7.81 16.1 ± 2.62 28.4 ± 1.51 45.2%
pMCI (n = 89) 52/37 73.2 ± 7.56 16.4 ± 2.47 26.9 ± 1.54 64.1%
P value 0.52a 0.045b 0.36c < 0.001b 0.0041a
Test dataset
(n = 255)
sMCI (n = 166) 85/81 70.6 ± 6.81 16.1 ± 2.64 28.4 ± 1.53 34.3%
pMCI (n = 89) 50/39 74.1 ± 6.21 15.5 ± 2.79 27.1 ± 2.03 73.0%
P value 0.45a 0.01b 0.11c <0.001b <0.001a
Cohort B HC (n = 50) 24/26 74.6 ± 3.17 15.8 ± 2.53 29.1 ± 1.01 28%
AD (n = 50) 28/22 74.8 ± 2.75 15.7 ± 2.64 23.1 ± 2.23 74%
P value 0.55a 0.71b 0.87c < 0.001b < 0.001a
Pa , the chi-square test; Pb , the two-sample t test; Pc , theWilcoxon rank-sum test. sMCI, stable MCI; pMCI, progressive MCI;MMSE, mini-mental state
examination; APOE ε4 positive rate, positive or negative for the presence of at least one ε4 allele
Data are given as mean ± SD
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KLSE validity assessment
To examine the validity of KLSE for metabolic network con-
struction, we compared results of KLSE with those of a con-
ventional group-level network estimation method by charac-
terizing pathological changes in the metabolic connection pat-
terns. We calculated the MCI-conversion patterns from the
individual- and group-level network seen in cohort A. The
group-level network was constructed using Pearson’s correla-
tion as described elsewhere [12, 14]. We obtained the meta-
bolic difference patterns associatedwith conversion fromMCI
to AD. In addition, we quantified and compared the number of
pathologically altered metabolic connectivity within brain re-
gions in MCI, respectively.
KLSE stability assessment
To further evaluate the network stability of KLSE, we per-
formed an inter-subject similarity analysis by defining two
subgroups from cohort A, each consisting of 20 sMCI subjects
or 20 pMCI subjects, who had otherwise similar demographic
characteristics. The similarity between the 20 metabolic net-
works derived from these 20 sMCI or pMCI subjects was
measured by averaging the correlation coefficients between
any pair of networks as follows:
R ¼ E corr F sp
 
; F sq
   	
; p; q∈1; 2;⋯20; p≠q ð3Þ
where F(sp) represents the vector of all metabolic connections
in subject p, corr indicates the Spearman rank correlation, and
E indicates the expected value or average value.
KLSE inter-individual dissimilarity
Cortical metabolic connection patterns vary between individ-
uals. Therefore, to determine the efficiency of KLSE in de-
scribing this heterogeneity, we explored inter-individual vari-
ations in metabolic networks of each brain region using a
previously proposed measure of dissimilarity [22, 23]. For a
given brain region i, the inter-individual dissimilarity between
the metabolic networks derived from MCI patients is estimat-
ed from the following formula:
Vi ¼ E 1−corr Fi sp
 
; Fi sq
   	
; p≠q ð4Þ
where Fi(sp) is a 1×90 vector of metabolic connectivities be-
tween region i and the other regions inMCI subject s, and corr
represents the Spearman rank-correlation. We applied Z-
normalization to the spatial maps of inter-individual dissimi-
larity to further compare the regional dissimilarity map.
KLSE application in MCI conversion
KLSE indicators extraction and selection
For the metabolic network of each subject, we calculated 457
network properties, of which seven are global network prop-
erties and 450 are regional network properties. The seven
global properties are clustering coefficient, characteristic path
length (L), small-worldness (S), global efficiency, transitivity,
assortativity coefficient, and modularity. We also examined
the regional network properties for a given node of the 90
VOIs for five other properties: betweenness centrality, degree,
local efficiency, vulnerability, and local clustering coefficient.
The details of these calculations are provided in Table A1.
These network properties were computed using the Brain
Connectivity Toolbox.
To identify the network properties associated with conver-
sion from MCI to AD, we applied an L1-penalized logistic
regression model based on the least absolute shrinkage and
selection operator (LASSO) to evaluate the contribution of
individual properties in the training dataset (cohort A).
Metabolic connectome expression (MCE), obtained by the
linear combination of the top network properties, provides
information about the interaction between VOIs and the spe-
cific metabolic abnormalities associated with the conversion
to AD. We used the test dataset (cohort A) to evaluate the
performance of the logistic regression model based
connectome method. The relative FDG uptake value in an
AD-meta-ROI was also implemented to compare the diagnos-
tic performance of our proposed connectome method [7].
Furthermore, we tested the connectome diagnostic perfor-
mance in cohort B, consisting of 50 AD patients and 50 age/
gender-matched healthy controls.
Cox model analysis
To consider different times to conversion among pMCI sub-
jects and to evaluate more strictly the metabolic connectome
expression as a predictive biomarker, we applied Cox propor-
tional hazard regression analysis to the clinical variables
(MMSE score, APOE ε4 genotype) and the metabolic
connectome expression derived from the training dataset in
cohort A. For each pMCI subject, we registered survival time
as the interval between the time of baseline PET imaging and
the time of initial AD diagnosis (or the last follow-up time for
sMCI subjects). The Z-statistic for each continuous covariate
was used to calculate a hazard ratio (HR) of the risk for con-
version as a function of the number of standard deviations of
an increase in the covariates. We then performed four multi-
variable Cox model analyses with age and sex as factors,
including the following variables: (1) clinical (MMSE,
APOE ε4), (2) metabolic connectome expression (MCE), (3)
group-level pattern expression score (PES) [8], and (4)
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combination of all variables (MMSE, APOE ε4, MCE). To
assess the model’s validity, each Cox model was applied in-
dependently to the test dataset.
We statistically evaluated the predictive performance of the
Cox model in terms of Harrell’s concordance index (C-index).
To evaluate the validity of a given Cox model, we applied the
Cox model to the test dataset and obtained the prognostic
index (PI) for each subject. To compare the hazard ratio
(HR) of each independent predictor variables and to test for
confounding variables also contributing to the model, we cal-
culated a Cox model including all indicators in the training
dataset. We also performed a Kaplan-Meier analysis of overall
survival to conversion using the PI values as a stratification
variable, with equally sized risk groups (low-risk and high-
risk) based on the ranked PI values.
Statistical analysis
Clinical and demographic characteristics were compared be-
tween groups using a two-sample t test, the chi-square test, or
theWilcoxon rank-sum test. Hazard ratios and associated 95%
confidence intervals (CIs) were evaluated using the Cox pro-
portional hazards regression model with Efron’s method.
Between-group differences in Kaplan-Meier overall survival
for MCI patients were evaluated using a log-rank test, strati-
fied as described above. All analyses were considered signif-
icant for P < 0.05 (2-tailed). The statistical analyses of
conversion-free survival were performed using R (version
3.61) employing the survival and glmnet packages.
Results
KLSE validation
KLSE validity assessment
We constructed a metabolic brain network from each subject’s
FDG-PET image using the KLSE method. There is compel-
ling similarity between individual- and group-level network
topographies in the pMCI group (Fig. 2a) and the sMCI group
(Fig. 2b). Metabolic patterns predictive of MCI-conversion at
the individual and group levels are shown in Fig. 2c, d. These
figures show that metabolic connectivity in the pMCI group
differs significantly from that in the sMCI group (P < 0.05,
FDR corrected). For individual-level metabolic patterns, we
found pathologically altered of patterns predictive of 5% for
the frontal connectivity, 13.7% for occipital connectivity,
26.4% for parietal connectivity and 13.9% for temporal lobe
connectivity. In the group-level metabolic patterns, corre-
sponding values were 17.7%, 13.6%, 10.9%, and 6.6%, re-
spectively. The pattern difference shows that our proposed
individual network method captures more than twice as many
changes in parietal and temporal lobes that are predictive of
conversion to AD relative to the typical group-level method.
Moreover, the novel application of the KLSE method discov-
ered a large number of abnormal metabolic connectivity find-
ings predictive of conversion in the precuneus, inferior tem-
poral, and posterior cingulate, this is in comparison to the
group-level analysis.
KLSE stability assessment
We explored the inter-subject network similarity in the sMCI
or pMCI groups. Here, the within-group similarity coefficient
of metabolic networks was 0.789 in the sMCI group, versus
0.731 in the pMCI group, indicating lower individual network
variability among those who progressed during follow-up,
suggesting that our proposed method has considerable stabil-
ity for detecting metabolic network architectures.
KLSE inter-individual dissimilarity
As shown in Fig. 3, we found that inter-individual dissimilar-
ity was higher in paracentral, angular, and olfactory regions in
the pMCI group, whereas dissimilar regions included the
paracentral, thalamic, and lingual regions in the sMCI group.
The mean inter-individual dissimilarity in parietal lobe was
higher than in the other lobes across the group of 178 pMCI
patients (all P < 0.01; Z-score, 0.766 for parietal, 0.123 for
occipital, − 0.303 for frontal and − 0.308 for temporal lobes).
Similar to findings in the pMCI group, the sMCI group
showed higher inter-individual dissimilarity in the parietal
lobe than in the other lobes (all P < 0.05; Z-scores, 0.616,
0.008, − 0.121 and − 0.528, respectively). These findings un-
derline that our individual-level network construction meth-
odology may detect more individual variation in the metabolic
network organization, thus capturing more idiosyncratic or
individual details.
KLSE methodology application in MCI conversion
Using the multivariate logistic regression method, we identi-
fied 13 local network properties associated with conversion
from MCI to AD. These properties were linearly combined in
the logistic regression model. However, this model did not
yield a significant between-group difference in all global prop-
erties (P > 0.05).
Average network properties for the sMCI and pMCI groups
in the training and test datasets showed significant between-
group differences (Fig. A4; P < 0.01). The network property
of vulnerability was significantly higher in pMCI subjects in
the precuneus, lingual, temporoparietal cortex, and precentral
gyrus relative to that in the sMCI subjects (P < 0.05). The
local efficiencies in inferior temporal gyrus and inferior frontal
cortex were significantly lower in the pMCI group relative to
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sMCI subjects, as was the property of betweenness centrality
in putamen (P < 0.05). There were no significant differences
in the other network properties between the sMCI and pMCI
groups (P > 0.05).
The MCE model differed significantly between sMCI and
pMCI groups with an AUC of 0.875 in the test dataset (Fig. 4a
and c), which is superior to conventional FDG uptake marker
(AUC, 0.721). Themetabolic connectomemodel gave distinct
results between HC and AD groups (Fig. 4b, P < 0.001). As
with the distinction between sMCI and pMCI groups, the
ROC analysis for the mixed HC/AD group once more showed
that MCE had excellent predictive performance (Fig. 4d,
AUC = 0.924).
Cox proportional hazards analysis
As summarized in Fig. 5, MCE, MMSE, and APOE ε4 status
all proved to be significant predictors for conversion from
Average KLSE 
network
Group-level 
network
Average KLSE 
network
Group-level 
network
Value
0.0
0.6
0.4
0.2
0.8
pMCI group sMCI group
Individual-metabolic difference pattern Group-metabolic difference pattern
a
dc
b
Fig. 2 Metabolic network topology in the pMCI group (a) and sMCI
group (b). The matrices represent the mean average metabolic network
based on the KLSE method (left triangle) and a group-level metabolic
network based on a conventional Pearson’s correlation method (right
triangle). The color intensity indicates the strength of metabolism
correlations. Metabolic difference patterns of predictive of MCI-
conversion are shown for individual- (c) and group-level (d) networks.
For calculating the individual-level pattern, we first applied Fisher’s Z-
transformation to the metabolic network of each MCI subject. Next, we
compared the Z-coefficients of the pMCI and sMCI groups using a two-
sample t test with false discovery rate (FDR) correction. For calculating
the corresponding group-level pattern, we likewise applied Fisher’s Z-
transformation and corrected P values for FDR. P < 0.05 was considered
significant. Each row (column) in the matrix corresponds to one of the 90
VOIs. Purple cells represent significantly different connectivity
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MCI toAD, withMCE emerging as the most significant factor
(HR, 3.55; 95% CI, 2.77–4.55; P < 0.001). Among the four
Cox models in Table A3, the performance of the imaging
connectome model revealed that MCE was a significant inde-
pendent predictor for conversion (HR, 3.80; 95% CI, 2.99–
4.82; P < 0.001) rather than traditional group-level model
(pattern model; pattern expression score-PES: HR, 3.18;
95% CI, 2.56–3.9). Age and sex were no significant variables
in clinical or combined models (P > 0.1). The imaging
connectomemodel had superior predictability over the clinical
model in the test dataset (C-index, 0.750 vs 0.728). As expect-
ed, the combined model also had superior predictive perfor-
mance in the test dataset (C-index, 0.794). Overall survival to
conversion was significantly prolonged in the low-risk group
compared to the high-risk group (HR, 9.074; 95% CI, 4.93–
16.7; P < 0.001) (Fig. 6).
Discussion
We present an individual-level metabolic network construct
approach for FDG-PET imaging and apply it to the task of
predicting individual risk of conversion from MCI to AD.
Recapitulating previous studies about MCI conversion predic-
tion, these works indeed have successfully differentiated pro-
dromal stages in MCI conversion. Nevertheless, such ap-
proaches cannot depict individual pathophysiology details
and downstream clinical therapeutic strategies, whereas the
ascendancy of our novel KLSE approach can afford individual
risk estimation. The symptoms of many neurological and psy-
chiatric diseases are mappable to specific functional networks
of interconnected brain regions.
Hitherto, all FDG-PET imaging studies of metabolic net-
works have used group-level analyses, which potentially
Fig. 3 Box and whisker plots of inter-individual dissimilarity of
metabolic networks across pMCI patients (N = 178) (a), and across
sMCI patients (N = 332) (b). Inter-individual dissimilarity is higher for
parietal lobe than other lobes in the pMCI group (c) (all P < 0.01) and the
sMCI (d) group (all P < 0.05)
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Fig. 4 The expression scores of metabolic connectome model (MCE)
was increased in pMCI groups compared with sMCI patients in test
dataset (a), and also higher in AD patients compared with healthy
people (b). ROC curve for metabolic connectome expression in cohort
A, i.e., progressive versus stable MCI (c) and cohort B, i.e., healthy
controls versus Alzheimer’s disease (d)
Fig. 5 Hazard ratios of different
predictors
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sacrifice or obscure salient individual differences within a
group. The KLSE approach has proven successful for individ-
ual structural MR-based analyses [16, 17], but has not yet
been applied to metabolic maps. Based on a calculation of
relative entropy, the KLSE can quantify the inter-regional
metabolic interactions for the construction of an individual’s
metabolic brain network. The putative association of FDG
metabolism with afferent synaptic activity implies that ele-
ments of the connectome are metabolically coupled [20, 24].
The intra-regional similarities calculated from KLSE in the
present case of FDG-PET are a surrogate measure of the met-
abolic connectivity between brain regions. In making a series
of evaluations of FDG-PET data from the extended ADNI
dataset, we evaluated the KLSE method’s validity and effec-
tiveness for predicting conversion ofMCI to AD, as compared
with a traditional group-level method based on Pearson’s cor-
relations. We found that the individualized metabolic KLSE
network analysis revealed subtle deviations in metabolic con-
nectivity that were powerfully predictive of conversion of
MCI to AD. Indeed, the KLSE method outperformed the tra-
ditional group-level approach for revealing patterns of altered
metabolic connectivity predictive of conversion. Our findings
of salient connectivity patterns in the parietal and occipital
lobes, recapitulate results of previous FDG-PET group-based
comparisons [8, 25]. In addition, we found that KLSE has
considerable intra-group stability for resolving metabolic net-
work organization, and highlights an especially pronounced
inter-individual dissimilarity of metabolic connectivity of the
parietal lobe of the pMCI group (Fig. 3). Overall, we find that
applying KLSE to FDG-PET data is a compelling approach
for revealing metabolic connectivity networks, having superi-
or performance relative to a traditional group-level method,
and revealing novel insights into the nature of metabolic dis-
turbances in the progression from MCI to AD.
In our analysis, we exploited a priori knowledge about the
clinical trajectory of 510 MCI patients in the ADNI database
to search for predictive patterns in the baseline FDG-PET
images. In so doing, we discriminated metabolic connectivity
patterns between sMCI and pMCI subgroups with roughly
similar baseline cognitive deficits. We explored the abnormal
metabolic network metrics associated with subsequent AD
conversion and used a logistic regression approach to develop
a metabolic connectome biomarker. We next validated this
biomarker relative to conventional clinical characteristics
and known risk factors using Cox proportional hazard regres-
sion models. Our composite model sensitively discriminated
sMCI and pMCI patients (AUC 0.827 for the test dataset)
from their baseline FDG-PET images, thus predicting their
risk of AD conversion during a 3-year follow-up. Notably,
there was a highly significant negative correlation between
MCE and clinical MMSE score for the composite population
(r = − 0.483, P < 0.001), indicating a strong link between
connectome expression and cognitive function (Fig. A5).
Because our present brain connectome approach can mea-
sure local network properties and the entire network, it could
powerfully identify salient properties predictive of conversion
from MCI to AD. In this regard, our main finding was that
conversion to AD entails disruption of modules (or subnet-
works) of the global network architecture and a loss of con-
nectivity between those modules. A number of previous PET
studies have likewise revealed an early failure of brain mod-
ules in relation to the onset of cognitive dysfunction [26]. In
the present work, we observed lower local efficiency in pMCI
compared to sMCI patients, particularly in inferior temporal
Fig. 6 Kaplan-Meier of overall
survival in test dataset of cohort A
for the combined model
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gyrus and inferior frontal cortex and higher vulnerability in
precuneus cortex, l ingual , precentral gyrus, and
temporoparietal cortex. With the progression of MCI, these
affected brain regions fail to metabolically compensate in
those MCI subjects destined to undergo further cognitive de-
cline. This latter result is consistent with previous studies
showing the failure of network components early in the neu-
rodegeneration process leading to AD [27]. Furthermore, we
tested for analogous changes of connectome properties in the
contrast between HC and AD patients, as summarized in Fig.
A6. As expected, the sMCI and pMCI groups occupied a
position in connectome topology intermediate to the HC and
AD groups. Our cross-sectional FDG PET data imply a pro-
gressive loss of connectivity in the metabolic network on the
trajectory to AD. Network properties in metabolic connectiv-
ity in precuneus, middle frontal region, and temporal pole
appeared to change progressively in our cross-sectional com-
parison of HC, sMCI, pMCI, and AD groups. The results are
in accord with previous MRI studies showing analogous net-
work changes in MCI conversion [27, 28].
Among the limitations of this study, we note that the end-
point of semi-quantitative FDG-PET is not entirely specific to
neuronal metabolism, but rather can reflect non-specific as-
pects of the progressive neurodegeneration progression [29].
The implementation of KLSE method of this work used for
FDG PET images without partial volume effect (PVE) correc-
tion. However, PVE correction can be used for metabolic net-
work construction, and the results agreed (Table A4). Our
interpretation of a link between metabolic network failure
and AD pathology remains to be confirmed by multimodal
imaging with tracers such as amyloid-β or tau deposition.
Therefore, future studies may require data other than the glu-
cose metabolism employed in the current study to fully verify
the applicability of metabolic connectome method.
Conclusion
This study presents an advanced connectome analysis of
FDG-PET images based on a novel application of KLSE en-
tropy measures, not previously applied to the task of metabol-
ic connectome analysis. This method sheds new light on the
network abnormality underlying the risk for conversion from
MCI to AD. Importantly, we present a novel prognostic score
for conversion risk that is additive to clinical risk stratification
procedures, attaining a C-index as high as 0.794 for the com-
bined model. By providing remarkably quantitative bio-
markers in individual subjects, the connectome model along
with clinical and metabolic pattern characteristics provides a
more comprehensive method to determining the risk in MCI
subjects to convert to AD in the coming years.
Acknowledgments We would like to gratefully acknowledge
Professor Paul Cumming for critical reading of the manuscript.
Data collection and sharing for this project was funded by the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National
Institutes of Health Grant U01 AG024904) and DOD ADNI
(Department of Defense award number W81XWH-12-2-0012).
ADNI is funded by the National Institute on Aging, the National
Institute of Biomedical Imaging and Bioengineering, and through
generous contributions from the following: AbbVie, Alzheimer’s
Association; Alzheimer’s Drug Discovery Foundation; Araclon
Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company;
CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli
Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its
affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO
Ltd.; Janssen Alzheimer Immunotherapy Research & Development,
LLC.; Johnson & Johnson Pharmaceutical Research & Development
LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale
Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies;
Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging;
Servier; Takeda Pharmaceutical Company; and Transition
Therapeutics. The Canadian Institutes of Health Research is providing
funds to support ADNI clinical sites in Canada. Private sector con-
tributions are facilitated by the Foundation for the National Institutes
of Health (www.fnih.org). The grantee organization is the Northern
California Institute for Research and Education, and the study is
coordinated by the Alzheimer’s Therapeutic Research Institute at
the University of Southern California. ADNI data are disseminated
by the Laboratory for Neuro Imaging at the University of Southern
California.
Funding information This study was supported by grants from the
National Natural Science Foundation of China (Nos.61603236,
81671239, 81401135, 81771483, and 81361120393), the National Key
Research and Development Program 428 of China (Nos.
2016YFC1306305, 2016YFC1306500, and 2018YFC1707704) from
Ministry of Science and Technology of China, Shanghai Technology
and Science Key Project in Healthcare (No. 17441902100), Science
and Technology Commiss ion of Shanghai Munic ipa l i ty
(17JC1401600), and Shanghai Municipal Science and Technology
Major Project (Grant No. 2017SHZDZX01).
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval All procedures performed in this study involving
human participants were following the ethical standards of the
institutional review boards of ADNI and with the 1964 Helsinki
declaration and its later amendments or comparable ethical
standards.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
2763Eur J Nucl Med Mol Imaging (2020) 47:2753–2764
References
1. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement.
2019;15(3):321–87. https://doi.org/10.1016/J.JALZ.2019.01.010.
2. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu
S, et al. Preclinical Alzheimer’s disease: definition, natural history,
and diagnostic criteria. Alzheimers Dement. 2016;12(3):292–323.
https://doi.org/10.1016/j.jalz.2016.02.002.
3. Sorensen A, Blazhenets G, Rucker G, Schiller F, Meyer PT, Frings
L. Prognosis of conversion of mild cognitive impairment to
Alzheimer’s dementia by voxel-wise Cox regression based on
FDG PET data. Neuroimage Clin. 2019;21:101637. https://doi.
org/10.1016/j.nicl.2018.101637.
4. Cabral C, Morgado PM, Campos Costa D, Silveira M. Predicting
conversion from MCI to AD with FDG-PET brain images at dif-
ferent prodromal stages. Comput BiolMed. 2015;58:101–9. https://
doi.org/10.1016/j.compbiomed.2015.01.003.
5. Zhou H, Jiang J, Lu J, Wang M, Zhang H, Zuo C. Dual-model
radiomic biomarkers predict development of mild cognitive impair-
ment progression to Alzheimer’s disease. Front Neurosci. 2018;12:
1045. https://doi.org/10.3389/fnins.2018.01045.
6. Choi H, Jin KH. Alzheimer’s disease neuroimaging I. predicting
cognitive decline with deep learning of brain metabolism and am-
yloid imaging. Behav Brain Res. 2018;344:103–9. https://doi.org/
10.1016/j.bbr.2018.02.017.
7. Pagani M, Nobili F, Morbelli S, Arnaldi D, Giuliani A, Oberg J,
et al. Early identification of MCI converting to AD: a FDG PET
study. Eur J Nucl MedMol Imaging. 2017;44(12):2042–52. https://
doi.org/10.1007/s00259-017-3761-x.
8. Blazhenets G, Ma Y, Sorensen A, Rucker G, Schiller F, Eidelberg
D, et al. Principal component analysis of brain metabolism predicts
development of Alzheimer’s dementia. J Nucl Med. 2018. https://
doi.org/10.2967/jnumed.118.219097.
9. Stam CJ. Modern network science of neurological disorders. Nat
Rev Neurosci. 2014;15(10):683–95. https://doi.org/10.1038/
nrn3801.
10. Grothe MJ, Teipel SJ. Spatial patterns of atrophy, hypometabolism,
and amyloid deposition in Alzheimer’s disease correspond to dis-
sociable functional brain networks. Hum Brain Mapp. 2016;37(1):
35–53. https://doi.org/10.1002/hbm.23018.
11. Choi H, Kim YK, Kang H, Lee H, Im HJ, Hwang DW, et al.
Abnormal metabolic connectivity in the pilocarpine-induced epi-
lepsy rat model: a multiscale network analysis based on persistent
homology. Neuroimage. 2014;99:226–36. https://doi.org/10.1016/
j.neuroimage.2014.05.039.
12. Titov D, Diehl-Schmid J, Shi K, Perneczky R, Zou N, Grimmer T,
et al. Metabolic connectivity for differential diagnosis of dementing
disorders. J Cereb Blood Flow Metab. 2017;37(1):252–62. https://
doi.org/10.1177/0271678x15622465.
13. Huang S, Li J, Sun L, Ye J, Fleisher A, Wu T, et al. Learning brain
connectivity of Alzheimer’s disease by sparse inverse covariance
estimation. Neuroimage. 2010;50(3):935–49. https://doi.org/10.
1016/j.neuroimage.2009.12.120.
14. Duan H, Jiang J, Xu J, Zhou H, Huang Z, Yu Z, et al. Differences in
Abeta brain networks in Alzheimer’s disease and healthy controls.
Brain Res. 2017;1655:77–89. https://doi.org/10.1016/j.brainres.
2016.11.019.
15. Tijms BM, Series P, Willshaw DJ, Lawrie SM. Similarity-based
extraction of individual networks from gray matter MRI scans.
Cereb Cortex. 2012;22(7):1530–41. https://doi.org/10.1093/
cercor/bhr221.
16. Wang H, Jin X, Zhang Y, Wang J. Single-subject morphological
brain networks: connectivity mapping, topological characterization
and test-retest reliability. Brain Behav. 2016;6(4):e00448. https://
doi.org/10.1002/brb3.448.
17. Kong XZ, Wang X, Huang L, Pu Y, Yang Z, Dang X, et al.
Measuring individual morphological relationship of cortical re-
gions. J Neurosci Methods. 2014;237:103–7. https://doi.org/10.
1016/j.jneumeth.2014.09.003.
18. Sokoloff L. Energetics of functional activation in neural tissues.
Neurochem Res. 1999;24(2):321–9. https://doi.org/10.1023/a:
1022534709672.
19. Lin TP, Carbon M, Tang C, Mogilner AY, Sterio D, Beric A, et al.
Metabolic correlates of subthalamic nucleus activity in Parkinson’s
disease. Brain. 2008;131(Pt 5):1373–80. https://doi.org/10.1093/
brain/awn031.
20. Raichle ME, Mintun MA. Brain work and brain imaging. Annu
Rev Neurosci. 2006;29:449–76. https://doi.org/10.1146/annurev.
neuro.29.051605.112819.
21. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR
Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s
disease: recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9. https://
doi.org/10.1016/j.jalz.2011.03.005.
22. Demirtas M, Burt JB, Helmer M, Ji JL, Adkinson BD, Glasser MF,
et al. Hierarchical heterogeneity across human cortex shapes large-
scale neural dynamics. Neuron. 2019;101(6):1181–94.e13. https://
doi.org/10.1016/j.neuron.2019.01.017.
23. Mueller S, Wang D, Fox MD, Yeo BT, Sepulcre J, Sabuncu MR,
et al. Individual variability in functional connectivity architecture of
the human brain. Neuron. 2013;77(3):586–95. https://doi.org/10.
1016/j.neuron.2012.12.028.
24. Ko JH, Spetsieris PG, Eidelberg D. Network structure and function
in Parkinson’s disease. Cereb Cortex. 2018;28(12):4121–35.
https://doi.org/10.1093/cercor/bhx267.
25. Petersen RC, Lundt ES, Therneau TM,Weigand SD, KnopmanDS,
Mielke MM, et al. Predicting progression to mild cognitive impair-
ment. Ann Neurol. 2019;85(1):155–60. https://doi.org/10.1002/
ana.25388.
26. Crossley NA,Mechelli A, Vertes PE,Winton-Brown TT, Patel AX,
Ginestet CE, et al. Cognitive relevance of the community structure
of the human brain functional coactivation network. Proc Natl Acad
Sci U S A. 2013;110(28):11583–8. https://doi.org/10.1073/pnas.
1220826110.
27. Brier MR, Thomas JB, Fagan AM, Hassenstab J, Holtzman DM,
Benzinger TL, et al. Functional connectivity and graph theory in
preclinical Alzheimer’s disease. Neurobiol Aging. 2014;35(4):757–
68. https://doi.org/10.1016/j.neurobiolaging.2013.10.081.
28. Raj A, Kuceyeski A, Weiner M. A network diffusion model of
disease progression in dementia. Neuron. 2012;73(6):1204–15.
https://doi.org/10.1016/j.neuron.2011.12.040.
29. Wei Y, Collin G, Mandl RCW, Cahn W, Keunen K, Schmidt R,
et al. Cortical magnetization transfer abnormalities and connectome
dysconnectivity in schizophrenia. Schizophr Res. 2018;192:172–8.
https://doi.org/10.1016/j.schres.2017.05.029.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
2764 Eur J Nucl Med Mol Imaging (2020) 47:2753–2764
